Bionano - Gang- Clubhouse Forum: Community User: Perstoper21

Gute Nacht 😉

Chemocentryx ist auch Risiko, wie halt fast jedes Investment. Aber bei ner Approval ist da viel Spielraum nach oben. Bei CRL geht 50% bergab. Da weiß man was man hat 😀 bin da lieber rausgegangen.

Per geht auch schon schlafen 😝

Bis morgen Leute 😎

Was soll mit Chemocentryx sein? Hab ich schon verkauft bei 16$ 😂

Drone pennt Bionano klettert ohne Seil Evo sucht den Star Halo kifft sich zum Mond Steinhoff schleift schonmal die Goldbarren

Welcher Star? Bestimmt Poldi 😂😂😂

DsCallez was ist mit Chemocentryx?

Na und dann ist da noch der Chart ;) danach richte ich mich hauptsächlich … buy low sell high - wann das high kommt , ist mir in dem Fall meistens egal ;)

Und sava läuft auch wieder.

Wer nicht wagt , der nicht gewinnt ;)

Net loss attributable to common stockholders improved to $33.4 million, or $(0.27) per share, for the quarter ended June 30, 2021, compared with a net loss of $46.2 million, or $(0.56) per share, in the first quarter of 2021 and a net loss of $52.7 million, or $(0.91) per share, for the prior year quarter. Cash and cash equivalents was $47.0 million at June 30, 2021. In addition, at June 30, 2021, $14.9 million in restricted cash from the Adjuvant notes was available for use.

Und als letztes :) :

Selling and marketing costs decreased 11% to $27.2 million, compared to $30.5 million in the first quarter of 2021 due primarily to lower media and agency fees, which were offset in part by costs related to the Phexxi sample rollout. General and administrative costs were $6.4 million compared to $7.7 million in the first quarter of 2021, primarily reflecting lower headcount, recruiting, and outside services. During the second quarter, the Company implemented cost containment measures across all departments. These included reductions in spend and headcount, elimination of certain consulting roles, and eliminating hires planned for 2021. These measures are expected to result in aggregate savings of $9.5 million on an annualized basis. Total other income, net, was $7.7 million in the second quarter of 2021, and mainly included a $8.9 million change in fair value as a result of mark-to-market adjustments and $1.2 million in interest expense for the convertible notes issued in 2020.

Financial Results For the three months ended June 30, 2021, Phexxi net product sales increased 68% to $1.9 million, compared to $1.1 million in the three months ended March 31, 2021. There were no net product sales in the second quarter of 2020, since Phexxi was launched in the U.S. in September 2020. Total operating expenses decreased 6% to $43.0 million for the second quarter of 2021 compared to $46.0 million in the first quarter of 2021. Cost of goods sold was $0.8 million, compared to $0.5 million in the first quarter of 2021, reflecting higher Phexxi sales. Research and development costs increased 17% to $8.5 million, compared to $7.3 million in the first quarter of 2021, reflecting higher enrollment in the Phase 3 EVOGUARD trial. This trial is funded in part by the proceeds from the Adjuvant convertible notes issued in 2020.

12,763 Phexxi® (lactic acid, citric acid and potassium bitartrate) prescriptions were filled and 14,810 units were dispensed to patients during the second quarter of 2021, an increase of 47% and 65%, respectively, compared to the first quarter of 2021. 52% growth in the prescriber base in the second quarter of 2021 compared to the first quarter of 2021, and over 7,700 healthcare providers have prescribed Phexxi from launch through mid-July. National brand ambassador campaign featuring an Emmy Award-winning celebrity launching in September 2021 to accelerate growth in Phexxi brand awareness and prescriptions. On track to complete enrollment in EVOGUARD by year-end 2021. This pivotal Phase 3 clinical trial is evaluating safety and efficacy of EVO100 for the prevention of chlamydia and gonorrhea in women.